Latham & Watkins represented Affer in the transaction. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has announced that it has entered into a definitive agreement...
Medtronic’s Acquisition of Affera
Royal Philips’ Acquisition of Vesper Medial
Latham & Watkins represented Vesper Medical in the transaction. Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, has signed an agreement to...
Galderma’s Acquisition of Alastin Skincare
Ropes & Gray advised Galderma on the deal, while Latham & Watkins advised ALASTIN. Galderma, one of the world’s largest independent dermatology companies, executed its acquisition...
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Procept BioRobotics’ $163.9 Million Initial Public Offering
Latham & Watkins represented PROCEPT in the transaction. PROCEPT BioRobotics Corporation, a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology,...
ZOLL Medical’s $538 Million Acquisition of Itamar Medical
Latham & Watkins and Goldfarb Seligman & Co. represented Itamar Medical in the transaction. Cooley and Gornitzky & Co. advised ZOLL Medical. Itamar™ Medical Ltd. (Nasdaq...
Eliem Therapeutics’ $80 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to...
European Wax Center’s $207.2 Million Initial Public Offering
Paul, Weiss advised European Wax Center, while Latham & Watkins represented the underwriters in the offering. European Wax Center, Inc. and certain selling stockholders executed its...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Imago BioSciences’ $134.4 Million Initial Public Offering
Latham & Watkins LLP represented Imago BioSciences, Inc. in the offering. Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...